Supplementary Table 1. Baseline characteristics of patients followed up and lost to follow up.
| Patients followed up | Patients lost to follow up | P-value | ||
|---|---|---|---|---|
| (n = 5,044) | (n = 1,106) | |||
| Demographics | ||||
| Age, year | 60.7 ± 9.9 | 62.0 ± 10.3 | < 0.001 | |
| Male | 4048 (80.3) | 876 (79.2) | 0.429 | |
| BMI, kg/m2 | 25.9 ± 3.0 | 25.6 ± 3.3 | 0.003 | |
| Medical history and risk factor | ||||
| Hypertension | 3434 (68.1) | 742 (67.1) | 0.522 | |
| Diabetes | 1753 (34.8) | 436 (39.4) | 0.003 | |
| Hyperlipidemia | 3110 (61.7) | 581 (52.5) | < 0.001 | |
| Previous MI | 1748 (34.7) | 456 (41.2) | < 0.001 | |
| Previous stroke | 505 (10.0) | 141 (12.7) | 0.007 | |
| COPD | 62 (1.2) | 14 (1.3) | 0.920 | |
| PAD | 456 (9.0) | 119 (10.8) | 0.075 | |
| CKD | 31 (0.6) | 26 (2.4) | < 0.001 | |
| Smoker | 2788 (55.3) | 604 (54.6) | 0.688 | |
| Clinical characteristic | ||||
| SAP | 1988 (39.4) | 418 (37.8) | 0.318 | |
| ACS | 3056 (60.6) | 688 (62.2) | 0.318 | |
| Left main involvement | 1131 (22.4) | 304 (27.5) | < 0.001 | |
| LVEF, % | 58.7 ± 9.2 | 56.7 ± 10.3 | < 0.001 | |
| Big ET-1, pmol/L | 0.65 (0.50–0.85) | 0.68 (0.52–1.01) | < 0.001 | |
| Troponin I, ng/mL | 0.03 (0.01–0.08) | 0.03 (0.02–0.13) | < 0.001 | |
| NT-proBNP, pmol/L | 622.2 (443.2–939.4) | 690.9 (462.0–1228.1) | < 0.001 | |
| hsCRP, mg/L | 2.01 (0.98–5.27) | 2.29 (1.05–6.19) | 0.015 | |
| Creatinine clearance, mL/min | 87.5 ± 27.5 | 83.0 ± 27.4 | < 0.001 | |
| Procedural characteristic | ||||
| SYNTAX score | ||||
| ≤ 22 | 1905 (37.8) | 350 (31.6) | < 0.001 | |
| 23–32 | 1841 (36.5) | 430 (38.9) | 0.137 | |
| ≥ 33 | 1148 (22.8) | 296 (26.8) | 0.004 | |
| Treatment | ||||
| MT | 1295 (25.7) | 395 (35.7) | < 0.001 | |
| PCI | 2168 (43.0) | 408 (36.9) | < 0.001 | |
| CABG | 1581 (31.3) | 303 (27.4) | 0.010 | |
| Medication at discharge | ||||
| Aspirin | 4871 (96.6) | 1037 (93.8) | < 0.001 | |
| Clopidogrel | 2758 (54.7) | 570 (51.5) | 0.058 | |
| ACEI | 1801 (35.7) | 414 (37.4) | 0.279 | |
| ARB | 816 (16.2) | 197 (17.8) | 0.185 | |
| Beta-blocker | 4469 (88.6) | 988 (89.3) | 0.486 | |
| CCB | 1681 (33.3) | 416 (37.6) | 0.006 | |
| Statin | 3388 (67.2) | 761 (68.8) | 0.292 | |
Values are presented as mean ± standard deviation, median (interquartile) or number (%).
ACEI, angiotensin-converting enzyme inhibitors; ACS, acute coronary syndrome; ARB, angiotensin II receptor blockers; BMI, body mass index; CABG, coronary artery bypass grafting; CCB, calcium channel blocker; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ET-1, endothelin-1; hsCRP, high sensitivity C reactive protein; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MT, medical therapy; NT-proBNP, N-terminal pro-B-Type natriuretic peptide; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; SAP, stable angina pectoris.